Health Canada has granted Dr. Reddy’s Laboratories a Notice of Compliance for a generic version of semaglutide injection, clearing the way for the first approved alternative to Novo Nordisk’s Ozempic in the country. The regulatory green light, confirmed in spring 2025, makes Canada one of the first major markets to authorize a lower-cost generic of the blockbuster diabetes and weight-loss drug at a time when patients across North America are struggling with persistent shortages and rising costs.
For the roughly 3.5 million Canadians living with type 2 diabetes, the approval could eventually translate into meaningful savings. Branded Ozempic currently costs approximately $250 to $300 CAD per month without insurance, according to pharmacy pricing data, and many patients have reported rationing doses or abandoning treatment altogether when supply runs dry. A generic alternative, if priced in line with typical generic discounts of 25% to 40% below brand, would ease that burden considerably.
What the approval actually means
A Notice of Compliance from Health Canada is the agency’s formal confirmation that a drug has met its standards for safety, efficacy, and manufacturing quality. For a generic injectable like Dr. Reddy’s semaglutide, that process includes a review of bioequivalence data showing the product performs comparably to branded Ozempic in the body.
The approval covers semaglutide injection for the treatment of type 2 diabetes, the same indication as Ozempic. It does not, based on available documentation, extend to chronic weight management, which is the approved use for Novo Nordisk’s separate brand, Wegovy. Whether physicians will prescribe the generic off-label for weight loss, as many already do with branded Ozempic, remains to be seen. Off-label prescribing is legal in Canada, but provincial drug plans typically do not cover medications used outside their approved indications.
Dr. Reddy’s, headquartered in Hyderabad, India, is one of the world’s largest generic pharmaceutical manufacturers, with an established presence in the Canadian market across dozens of therapeutic categories. The company has not yet disclosed a specific launch date, production volumes for Canada, or its pricing strategy. Those details will determine how quickly the generic moves from regulatory approval to pharmacy shelves.
Why supply has been so strained
The approval arrives against a backdrop of chronic semaglutide shortages that have frustrated patients and pharmacists for more than two years. Novo Nordisk has repeatedly acknowledged that global demand for Ozempic and Wegovy has outpaced its manufacturing capacity. The company has invested billions in expanding production facilities in Denmark and the United States, but new capacity takes years to come online.
In Canada, the shortage has been compounded by cross-border demand. American patients, facing even higher prices in the U.S., have turned to Canadian pharmacies and online services to fill prescriptions at lower cost. Canada’s drug shortage framework includes provisions to restrict exports when domestic supply is at risk, but enforcement has been inconsistent, and no official statement has addressed whether the new generic will be subject to additional export controls.
The scarcity has also created openings for dangerous counterfeits. The U.S. Food and Drug Administration has issued direct warnings about fake Ozempic pens discovered in the American drug supply chain. These products mimicked genuine packaging but contained unknown substances or incorrect concentrations of semaglutide, posing risks including dangerously low blood sugar. The FDA urged patients to obtain the drug only through licensed pharmacies and to report suspected counterfeits through its MedWatch system or the federal safety reporting portal.
The gap between approval and access
Regulatory clearance is a necessary first step, but it does not guarantee immediate availability. Several hurdles stand between the Notice of Compliance and a patient picking up a generic semaglutide pen at a local pharmacy.
First, Dr. Reddy’s must finalize manufacturing and distribution logistics. Semaglutide is a synthetic peptide that requires cold-chain storage and specialized packaging, making its supply chain more complex than a typical oral generic. Second, the generic needs to be listed on provincial drug formularies to be covered by public insurance plans. Each province negotiates pricing independently through the pan-Canadian Pharmaceutical Alliance, and that process can take months. Third, private insurers will need to update their own coverage policies, which often lag behind public formulary decisions.
Novo Nordisk’s competitive response adds another layer of uncertainty. The Danish company could lower its Canadian pricing for Ozempic, accelerate its own supply recovery, or pursue legal strategies related to patent protection and market exclusivity. As of May 2026, Novo Nordisk has not issued a public statement responding to the generic approval. How aggressively the company defends its market position will influence both pricing and the speed at which the generic gains insurance coverage.
What other countries are doing
Canada’s move puts it ahead of the United States, where no generic semaglutide injection has received FDA approval. American patients currently face list prices exceeding $900 USD per month for Ozempic, and while compounding pharmacies have stepped in to fill the gap with custom-made semaglutide formulations, the FDA has signaled it may restrict that practice as Novo Nordisk’s supply stabilizes.
In other markets, the picture is mixed. India, where Dr. Reddy’s is based, already has multiple domestic semaglutide products available at a fraction of Western prices. Several European regulators are reviewing generic and biosimilar applications, though none had issued approvals as of early 2026. Canada’s decision could accelerate those timelines by establishing a regulatory precedent and generating real-world safety and efficacy data for a generic semaglutide product.
What patients should do right now
For Canadians currently taking Ozempic, the practical advice is straightforward: keep filling prescriptions as usual and ask your pharmacist or prescriber to flag updates on generic availability. Switching from a branded drug to a generic requires a conversation with your healthcare provider, not a unilateral decision, especially for an injectable medication where pen devices and dosing protocols may differ slightly between manufacturers.
Patients paying out of pocket should watch for formulary announcements from their provincial drug plan, since public coverage of the generic would likely deliver the most significant cost relief. Those with private insurance should contact their plan administrator to ask whether the generic will be added to their coverage list and on what timeline.
For patients in the United States, the FDA’s counterfeit warning remains urgent. Semaglutide should only be obtained through licensed pharmacies and authorized distributors. Pens purchased through social media, online marketplaces, or informal channels carry real risks. Anyone who suspects they have received a counterfeit product should stop using it, contact a healthcare provider, and file a report through official FDA channels.
Across both countries, the fundamental tension has not changed: demand for semaglutide far exceeds regulated supply, and that gap creates opportunities for both legitimate competitors and bad actors. Canada’s approval of a generic is a concrete step toward closing that gap through the regulatory system. How quickly it translates into cheaper, more accessible medication for the patients who need it will depend on manufacturing timelines, insurance negotiations, and policy decisions that are still months away from resolution.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
